Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126211991 | 12621199 | 1 | I | 20160716 | 20160718 | 20160804 | 20160804 | PER | US-PFIZER INC-2016350284 | PFIZER | 77.00 | YR | M | Y | 86.18000 | KG | 20160804 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126211991 | 12621199 | 1 | PS | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, 2X/DAY | 2400 | MG | N | 20235 | 300 | MG | CAPSULE, HARD | BID | |||
| 126211991 | 12621199 | 2 | C | VALACYCLOVIR HCL | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 1 MG, 3X/DAY | 0 | 1 | MG | TABLET | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126211991 | 12621199 | 1 | Herpes zoster |
| 126211991 | 12621199 | 2 | Herpes zoster |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126211991 | 12621199 | Intentional product misuse | |
| 126211991 | 12621199 | Oedema peripheral |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126211991 | 12621199 | 1 | 20160713 | 20160718 | 0 | |
| 126211991 | 12621199 | 2 | 20160713 | 0 |